EyePoint’s Duravyu falls short to Eylea in Phase III trial

Phase 3negativeDuravyuEyleaNegative

AI Analysis

Summary

EyePoint's Duravyu failed to demonstrate superiority over Regeneron's Eylea in a Phase III trial for wet age-related macular degeneration. The negative outcome significantly impacts EyePoint's wet AMD market entry plans.

Clinical Trial Data

Phase

Phase III

Primary Endpoint

Not Met

Outcome Details

Duravyu fell short to Eylea in Phase III trial

Importance:7/10

Sentiment:

-0.80

Phase 3wet AMDophthalmologyfailed trialcompetitive threat

Related Companies

$TRAX $ARNA

Read the original article

Published by Clinical Trials Arena on August 18, 2026 1:40 PM

Read Original